Literature DB >> 28453744

Significance of low mTORC1 activity in defining the characteristics of brain tumor stem cells.

Yi-Peng Han1,2, Atsushi Enomoto1, Yukihiro Shiraki1, Shen-Qi Wang3, Xiaoze Wang1, Shinya Toyokuni3, Naoya Asai1, Kaori Ushida1, Hosne Ara1, Fumiharu Ohka4, Toshihiko Wakabayashi4, Jie Ma2, Atsushi Natsume4, Masahide Takahashi1.   

Abstract

Background: The significance of mammalian target of rapamycin complex 1 (mTORC1) activity in the maintenance of cancer stem cells (CSCs) remains controversial. Previous findings showed that mTORC1 activation depleted the population of leukemia stem cells in leukemia, while maintaining the stemness in pancreatic CSCs. The purpose of this study was to examine the currently unknown role and significance of mTORC1 activity in brain tumor stem cells (BTSCs).
Methods: Basal mTORC1 activity and its kinetics were investigated in BTSC clones isolated from patients with glioblastoma and their differentiated progenies (DIFFs). The effects of nutrient deprivation and the mTORC1 inhibitors on cell proliferation were compared between the BTSCs and DIFFs. Tissue sections from patients with brain gliomas were examined for expression of BTSC markers and mTORC1 activity by immunohistochemistry.
Results: BTSCs presented lower basal mTORC1 activity under each culture condition tested and a more rapid decline of mTORC1 activity after nutrient deprivation than observed in DIFFs. The self-renewal capacity of BTSCs was unaffected by mTORC1 inhibition, whereas it effectively suppressed DIFF proliferation. In agreement, immunohistochemical staining of glioma tissues revealed low mTORC1 activity in tumor cells positive for BTSC markers. In in vitro culture, BTSCs exhibited resistance to the antitumor agent temozolomide. Conclusions: Our findings indicated the importance of low mTORC1 activity in maintaining the undifferentiated state of BTSCs, implicating the relevance of manipulating mTORC1 activity when developing future strategies that target BTSCs.
© The Author(s) 2016. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

Entities:  

Keywords:  brain tumor stem cell; cancer stem cell; glioma; mTORC1

Mesh:

Substances:

Year:  2017        PMID: 28453744      PMCID: PMC5464440          DOI: 10.1093/neuonc/now237

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  39 in total

1.  Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells.

Authors:  Yuanyan Wei; Yizhou Jiang; Fei Zou; Yingchao Liu; Shanshan Wang; Nuo Xu; Wenlong Xu; Chunhong Cui; Yang Xing; Ying Liu; Benjin Cao; Chanjuan Liu; Guoqiang Wu; Hong Ao; Xiaobiao Zhang; Jianhai Jiang
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-08       Impact factor: 11.205

2.  Contribution of microRNA-1275 to Claudin11 protein suppression via a polycomb-mediated silencing mechanism in human glioma stem-like cells.

Authors:  Keisuke Katsushima; Keiko Shinjo; Atsushi Natsume; Fumiharu Ohka; Makiko Fujii; Hirotaka Osada; Yoshitaka Sekido; Yutaka Kondo
Journal:  J Biol Chem       Date:  2012-06-26       Impact factor: 5.157

Review 3.  Regulation of cancer cell metabolism.

Authors:  Rob A Cairns; Isaac S Harris; Tak W Mak
Journal:  Nat Rev Cancer       Date:  2011-02       Impact factor: 60.716

4.  Eyes wide open: a critical review of sphere-formation as an assay for stem cells.

Authors:  Erika Pastrana; Violeta Silva-Vargas; Fiona Doetsch
Journal:  Cell Stem Cell       Date:  2011-05-06       Impact factor: 24.633

Review 5.  Current treatment strategies for inhibiting mTOR in cancer.

Authors:  Francesca Chiarini; Camilla Evangelisti; James A McCubrey; Alberto M Martelli
Journal:  Trends Pharmacol Sci       Date:  2014-12-11       Impact factor: 14.819

Review 6.  Targeting cancer stem cells to suppress acquired chemotherapy resistance.

Authors:  S J Vidal; V Rodriguez-Bravo; M Galsky; C Cordon-Cardo; J Domingo-Domenech
Journal:  Oncogene       Date:  2013-10-07       Impact factor: 9.867

7.  Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro.

Authors:  Tatyana N Ignatova; Valery G Kukekov; Eric D Laywell; Oleg N Suslov; Frank D Vrionis; Dennis A Steindler
Journal:  Glia       Date:  2002-09       Impact factor: 7.452

8.  CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells.

Authors:  Jian Wang; Per Ø Sakariassen; Oleg Tsinkalovsky; Heike Immervoll; Stig Ove Bøe; Agnete Svendsen; Lars Prestegarden; Gro Røsland; Frits Thorsen; Linda Stuhr; Anders Molven; Rolf Bjerkvig; Per Ø Enger
Journal:  Int J Cancer       Date:  2008-02-15       Impact factor: 7.396

Review 9.  How cancer metabolism is tuned for proliferation and vulnerable to disruption.

Authors:  Almut Schulze; Adrian L Harris
Journal:  Nature       Date:  2012-11-15       Impact factor: 49.962

10.  mTOR plays critical roles in pancreatic cancer stem cells through specific and stemness-related functions.

Authors:  Shyuichiro Matsubara; Qiang Ding; Yumi Miyazaki; Taisaku Kuwahata; Koichiro Tsukasa; Sonshin Takao
Journal:  Sci Rep       Date:  2013-11-15       Impact factor: 4.379

View more
  3 in total

1.  CDK7 inhibition is a novel therapeutic strategy against GBM both in vitro and in vivo.

Authors:  Wei Meng; Jiajia Wang; Baocheng Wang; Fang Liu; Meng Li; Yang Zhao; Chenran Zhang; Qifeng Li; Juxiang Chen; Liye Zhang; Yujie Tang; Jie Ma
Journal:  Cancer Manag Res       Date:  2018-11-15       Impact factor: 3.989

2.  Novel mTORC1 Inhibitors Kill Glioblastoma Stem Cells.

Authors:  Jose A Sandoval; Alexey Tomilov; Sandipan Datta; Sonia Allen; Robert O'Donnell; Thomas Sears; Kevin Woolard; Dmytro Kovalskyy; James M Angelastro; Gino Cortopassi
Journal:  Pharmaceuticals (Basel)       Date:  2020-11-24

3.  Complex roles of the actin-binding protein Girdin/GIV in DNA damage-induced apoptosis of cancer cells.

Authors:  Chen Chen; Atsushi Enomoto; Liang Weng; Tetsuro Taki; Yukihiro Shiraki; Shinji Mii; Ryosuke Ichihara; Mitsuro Kanda; Masahiko Koike; Yasuhiro Kodera; Masahide Takahashi
Journal:  Cancer Sci       Date:  2020-09-19       Impact factor: 6.716

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.